The U.S. Food and Drug Administration (FDA) recently approved the use of enfortumab vedotin-ejfv, together with pembrolizumab for patients with locally advanced or metastatic urothelial cancer. Results from a randomized study of 886 patients indicated "statistically significant improvements in both overall survival and progression-free survival (31.5 months on average) compared to platinum-based chemotherapy (16.1 months)."
To learn more about this study, click here.
No comments:
Post a Comment